bioMérieux is a family-owned company specializing in in vitro diagnostics, providing solutions for pathogen detection and identification to healthcare professionals and industry players. The company develops and manufactures diagnostic tests and instruments for clinical microbiology, molecular diagnostics, and point-of-care testing, serving markets in Europe, the Middle East, Africa, and globally. Key product lines include the BIOFIRE and FILMARRAY platforms for respiratory and pneumonia panels, the SPINCHIP point-of-care platform for cardiac troponin measurement, and solutions for antimicrobial resistance and pharmaceutical quality control. bioMérieux supports public health initiatives, including rapid diagnostics for Ebola response and sepsis management, and operates a distribution network across multiple regions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage biomerieux.com
Sector Healthcare IR page biomerieux.com/corp/en/investors.html
Tags
in vitro diagnostics, clinical microbiology, molecular diagnostics, point-of-care testing, antimicrobial resistance, respiratory diagnostics, sepsis diagnostics, pharmaceutical quality control, pathogen detection, public health, BIOFIRE, FILMARRAY, SPINCHIP, GO•28
Press page —

Metrics

Valuation  
Market cap € 11.319B
Market cap (USD) $ 12.51B
P/E 24.47
PEG —
P/BV 2.76
P/S 2.77
P/OCF 14.36
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 9.6%
ROI 9.7%
ROIC 9.5%
Profit margin 9.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -4.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 13
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2012 FY 2011 FY 2010
Revenue 4.07B 3.98B 3.675B 3.589B 3.376B 3.118B 2.675B 1.57B 1.427B 1.357B
Net profit 397.5M 432.2M 357.6M 452.4M 601.1M 404.4M 272.8M 134.4M 158.2M 158.7M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2012 FY 2011 FY 2010
Share price 114.54 117.3 96.03 100.03 86.82 121.38 103.1 — — —
Price performance 12m -0.02 0.22 -0.04 0.15 -0.28 0.18 — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Other receivables (EUR) 61.1M 82.2M 118M 153M 172M 176M 179M
Cash and deposits (EUR) 275M 389M 804M 553M 352M 450M 570M
Intangible assets (EUR) 508M 431M 412M 625M 529M 492M 402M
Right-of-use assets (EUR) 131M 130M 124M 120M 149M 170M 141M
Cash flow detail
Operating cash flow (EUR) 408M 583M 811M 475M 445M 667M 788M
Purchases of property, plant and equipment (EUR) -273M -278M -290M -287M -338M -346M -335M
Change in receivables (cash effect) (EUR) -400,000 -500,000 -2.7M -500,000 500,000 -3.7M -4.6M
Change in inventories (cash effect) (EUR) 71M 82.9M 62.4M 92.1M -193M -85.1M -10.1M
Change in payables (cash effect) (EUR) -32.9M -4.7M -24.2M -9.9M 3.4M -600,000 3.4M
Dividends paid (cash effect) (EUR) -41.3M -22.5M -73.1M -101M -100M -100M -106M
Share buybacks (cash effect) (EUR) 0.00 -18.4M -3.8M -157M -12.7M -37.6M -18.2M
Income taxes paid (cash effect) (EUR) 81.6M 116M 185M 224M -204M -206M -152M
Share-based compensation (EUR) 9.4M 9.9M 12.4M 13M 19.7M 23.4M 26.5M
Operating cash flow before change in receivables (EUR) 408M 583M 814M 476M 445M 671M 793M
Free cash flow (OCF - PPE - intangibles) (EUR) 135M 305M 521M 188M 107M 322M 453M
Income detail
Research and development expense (EUR) 374M 399M 389M 447M 460M 492M 507M
↳ 5y CAGR +5.6% +4.9%
Total comprehensive income (EUR) 287M 251M 761M 585M 183M 574M -5.1M
Comprehensive income to owners (EUR) 289M 254M 760M 597M 219M 581M -3M
Reported Mar 17, 2021 Mar 17, 2021 Mar 17, 2022 Mar 22, 2023 Mar 27, 2024 Mar 21, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

bioMérieux – Third-Quarter 2026 Business Review Bull 3 Bear 0 Results

Prompts

Biomerieux (ticker BIM), listed in France.

ETFs Holding Biomerieux

ETF Weight in ETF Shares Market value As of
SAGP 1.51% 14,764 $ 1.16M Jun 30, 2026
QLTI 0.93% 31,667 $ 2.761M Aug 31, 2026
DFIS 0.07% 40,301 $ 4.116M Nov 12, 2026
AVDE 0.05% 89,221 $ 9.005M Nov 16, 2026
AVSD 0.04% 1,385 $ 139.785K Nov 16, 2026
DFIC 0.02% 31,345 $ 3.202M Nov 12, 2026
DFAX 0.01% 17,645 $ 1.802M Nov 12, 2026
DFAI 0.01% 23,391 $ 2.389M Nov 12, 2026
DFSI 0.00% 389 $ 39.734K Nov 12, 2026